blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3326616

EP3326616 - LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.06.2022
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  25.06.2021
FormerGrant of patent is intended
Status updated on  23.03.2021
FormerExamination is in progress
Status updated on  28.05.2019
FormerRequest for examination was made
Status updated on  30.11.2018
FormerThe application has been published
Status updated on  27.04.2018
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Signpath Pharma Inc.
9710 Ruskin Circle
Sandy, UT 84092 / US
[2018/22]
Inventor(s)01 / HELSON, Lawrence
1375 California Road
Quakertown, PA Pennsylvania 18951 / US
 [2018/22]
Representative(s)SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
[N/P]
Former [2018/22]Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
Application number, filing date17202117.203.06.2012
[2018/22]
Priority number, dateUS201161493257P03.06.2011         Original published format: US 201161493257 P
[2018/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3326616
Date:30.05.2018
Language:EN
[2018/22]
Type: B1 Patent specification 
No.:EP3326616
Date:28.07.2021
Language:EN
[2021/30]
Search report(s)(Supplementary) European search report - dispatched on:EP28.03.2018
ClassificationIPC:A61K9/127, A61P9/00, A61P9/04, A61K31/12, A61K31/445, A61K31/18
[2021/09]
CPC:
A61K9/127 (EP,US); A61K31/12 (EP,US); A61K31/18 (EP);
A61K31/445 (EP,US); A61P9/00 (EP); A61P9/04 (EP)
Former IPC [2018/22]A61K9/127, A61K31/34, A61K31/445, A61K31/366, A61K31/7042, A61K31/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/15]
Former [2019/01]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Former [2018/22]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:LIPOSOMALE ABSCHWÄCHUNG DES ARZNEIMITTELINDUZIERTEN LONG-QT-SYNDROMS MITTELS STROM AUS EINEM DURCH KALIUM VERZÖGERTEN UMRICHTER[2018/22]
English:LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT[2018/22]
French:ATTÉNUATION LIPOSOMALE DU SYNDROME DU QT LONG INDUIT PAR UN MÉDICAMENT ET DU COURANT DE POTASSIUM À REDRESSEMENT RETARDÉ[2018/22]
Examination procedure22.11.2018Amendment by applicant (claims and/or description)
22.11.2018Examination requested  [2019/01]
22.11.2018Date on which the examining division has become responsible
03.06.2019Despatch of a communication from the examining division (Time limit: M06)
02.12.2019Reply to a communication from the examining division
09.03.2020Despatch of a communication from the examining division (Time limit: M06)
09.09.2020Reply to a communication from the examining division
24.03.2021Communication of intention to grant the patent
21.06.2021Fee for grant paid
21.06.2021Fee for publishing/printing paid
21.06.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP12792560.0  / EP2714011
Opposition(s)29.04.2022No opposition filed within time limit [2022/27]
Fees paidRenewal fee
16.11.2017Renewal fee patent year 03
16.11.2017Renewal fee patent year 04
16.11.2017Renewal fee patent year 05
16.11.2017Renewal fee patent year 06
07.06.2018Renewal fee patent year 07
12.06.2019Renewal fee patent year 08
23.06.2020Renewal fee patent year 09
10.06.2021Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.06.2012
AL28.07.2021
CY28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
MK28.07.2021
MT28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
[2024/42]
Former [2024/22]HU03.06.2012
AL28.07.2021
CY28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
MK28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2024/20]HU03.06.2012
AL28.07.2021
CY28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2024/18]HU03.06.2012
AL28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2023/08]AL28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/29]AL28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/25]CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SK28.07.2021
SM28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/24]CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
NL28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SK28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/21]DK28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
NL28.07.2021
PL28.07.2021
RS28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/10]FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
NL28.07.2021
PL28.07.2021
RS28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/09]FI28.07.2021
LT28.07.2021
NL28.07.2021
RS28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
PT29.11.2021
Former [2022/08]FI28.07.2021
LT28.07.2021
NL28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
Former [2022/07]LT28.07.2021
NL28.07.2021
NO28.10.2021
Documents cited:Search[XI]US5023087  (YAU-YOUNG ANNIE [US]) [X] 1-9,14 * example 8; claim 1 * [I] 10-13,15;
 [XI]US2010093873  (GOLDFISCHER SIDNEY L [US]) [X] 1-9,13,14 * paragraphs [0006] , [0015]; claim 1 * [I] 10-12,15;
 [A]US2005233970  (GARNICK MARC B [US]) [A] 1-15 * the whole document *
 [X]  - MAYER L D ET AL, "INTRAVENOUS PRETREATMENT WITH EMPTY PH GRADIENT LIPOSOMES ALTERS THE PHARMACOKINETICS AND TOXICITY OF DOXORUBICIN THROUGH IN VIVO ACTIVE DRUG ENCAPSULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (19990101), vol. 88, no. 1, doi:10.1021/JS980202H, ISSN 0022-3549, pages 96 - 102, XP000789043 [X] 1-15 * Abstract; page 97, left column paragraph 2 *

DOI:   http://dx.doi.org/10.1021/js980202h
 [A]  - T. NOUSIAINEN ET AL, "QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma", JOURNAL OF INTERNAL MEDICINE, (19990401), vol. 245, no. 4, doi:10.1046/j.1365-2796.1999.00480.x, ISSN 0954-6820, pages 359 - 364, XP055148526 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1046/j.1365-2796.1999.00480.x
ExaminationEP2133074
by applicantUS2010004549
 US2008255464
 US2007048284
 US2010120890
 US5679864
    - ANDERSON CL.; DELISLE BP; ANSON BD, "Most LQT2 Mutations Reduce Kvl 1.1 (hERG) Current by a class2 (Trafficking Deficient) Mechanism", Circulation, (20060000), vol. 113, pages 365 - 373
    - COMPTONSJ; LUX RL; RAMSEY MR et al., "Genetically defined therapy of inherited long QT syndrome", Correction of abnormal repolarization by potassium, (19960000), vol. 94, pages 1018 - 1022
    - DJEDDI D; KONGOLO G; LEFAIX C; MOUNARD J; LEKE A, "Effect of domperidone on QT interval in neonates", J Pediatrics, (20080000), vol. 153, no. 5, doi:doi:10.1016/j.jpeds.2008.05.013, pages 596 - 598, XP025779944

DOI:   http://dx.doi.org/10.1016/j.jpeds.2008.05.013
    - DUCROQ J.; PRINTEMPS R; LE GRAND M., "Additive effects ziprasidone and D,L-sotalol on the action potential in rabbit purkinje fibers and on the hERG potassium current", J.Pharmacol. Toxicol Methods, (20050000), vol. 52, doi:doi:10.1016/j.vascn.2005.04.001, pages 115 - 122, XP004985398

DOI:   http://dx.doi.org/10.1016/j.vascn.2005.04.001
    - ETHERIDGE SP; COMPTON SJ; TRISTANI-FIROUZI M; MASON JW, "A new oral therapy for long QT syndrome: long term oral potassium improves repolarization in patients with hERG mutations", J AM Coll Cardiol, (20030000), vol. 42, pages 1777 - 1782
    - FAUCHIER L; BABUTY D; PORET P; AUTRET ML; COSNAY P; FAUCHIER JP, "Effect of Verapamil on QT interval dynamicity", AM J Cardiol., (19990000), vol. 83, no. 5, pages 807 - 808
    - FOWLER NO; MCCALL D; CHOU TC; HILMES JC; HANENSON IB, "Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs", Am J Cardiol, (19760000), vol. 37, no. 2, doi:doi:10.1016/0002-9149(76)90316-7, pages 223 - 230, XP026333604

DOI:   http://dx.doi.org/10.1016/0002-9149(76)90316-7
    - JERVELL A; LANG-NIELSON F, "Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death", Am Heart J., (19570000), vol. 54, doi:doi:10.1016/0002-8703(57)90079-0, pages 59 - 68, XP022944336

DOI:   http://dx.doi.org/10.1016/0002-8703(57)90079-0
    - KANG J; CHEN XL; WANG H et al., "Discovery of a small molecule activator of the human ether-a-go-go - related gene(HERG) cardiac K+ channel", Mol Pharmacol, (20050000), vol. 67, doi:doi:10.1124/mol.104.006577, pages 827 - 836, XP002556830

DOI:   http://dx.doi.org/10.1124/mol.104.006577
    - KATCHMAN AN; KOERNER J; TOSAKA T; WOOSLEY RL; EBERTY SN, "Comparative evaluation of HERG currents and QWT intervals following challenge with suspected torsadogenic and non-torsdogenic drugs", J Pharmacol Exp Ther., (20060000), vol. 316, no. 3, pages 1098 - 1106
    - LAYTON D; KEY C; SHAKIR SA, "Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future", Pharmacoepidemiol Drug Saf., (20030000), vol. 12, no. 1, pages 31 - 40
    - MACIEL NR; REIS PG; KATO KC et al., "Reduced cardio-vascular alterations of tarter emetic administered in long-circulating liposomes in rats", Toxicology Letters, (20100000), vol. 199, no. 3, pages 234 - 238
    - MEHTA RT; HOPFER RL; GUNNER LA; JULIANO RL; LOPEZ-BERESTEIN G, "Formulation, toxicity ,and antifungal activity in vitro of liposomal-encapsulated nystatin as therapeutic agent for systemic candidiasis", Antimicrob Agents Chemother., (19870000), vol. 31, no. 12, pages 1897 - 1900
    - MOHA OU MAATI H; DUCROQ J; RIVET J; FAIVRE J.F; LE GRANDE M; BOIS P, "Curcumin blocks the recombinant human cardiac KCNQ1/ KCNE1 channels (IKs) stably expressed in HEK 293 cells. Congress de Physiologie,de Pharmacologie et de Therapeutique", Fund. Clin. Pharmacol., (20080409), vol. 22, no. l
    - SHIMIZU W; ANTZELEVITCH C, "Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long QT syndrome", Circulation, (19970000), vol. 96, pages 2038 - 2047
    - SHIMIZU W; ANTZELEVITCH C, "Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes LQT1, LQT2, and LQT3 models of the long QT syndrome", Circulation, (20000000), vol. 102, pages 702 - 712
    - STANSFELD PJ; GEDECK P; GOSLING M; COX B; MITCHESON JS; SUTCLIF MJ, "Drug block of the hERG potassium Channel: insight from modeling", Proteins, (20070000), vol. 68, no. 2, pages 568 - 580
    - QUAN XQ; BAI R; LIU N; CHEN BD; ZHANG CT, "Increasing gap junction coupling reduces transmural dispersion of repolarization and prevents torsades de points in rabbit LQT3 model", J Cardiovasc Electrophysiol, (20070000), vol. 18, pages 1184 - 1189
    - ZAVHARIAE U; GIORDANETTO F; LEACH AG, "Side chain flexabilities in the human ether-a-go-go related potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers", J Med Chem, (20090000), vol. 52, no. 14, pages 4266 - 4276
    - ZHOU Z; GONG Q, "January CT: Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome: Pharmacological and temperature effects", J Biol Chem., (19990000), vol. 274, doi:doi:10.1074/jbc.274.44.31123, pages 31123 - 31126, XP002281088

DOI:   http://dx.doi.org/10.1074/jbc.274.44.31123
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.